ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Mouse Models, Other"

  • Abstract Number: 1799 • ACR Convergence 2025

    Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies

    Xiao-Na Ma1, Mei-Feng Shi1, Qian Chen1, Fang-Shu Zou1, Wei Feng1, Qing-Ping Liu1, Chang-Song Lin1, Nan Li2, Xiao-Bao Liu1 and Qiang Xu1, 1Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), 2School of Traditional Chinese Medicine, Jinan University, Guangzhou, China (People's Republic)

    Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…
  • Abstract Number: 1790 • ACR Convergence 2025

    Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis

    Lai Wang1, alia obeidat2, Shingo Ishihara3, Jun Li2, Frank Ko2, Terese Geraghty2, Natalie Adamczyk3, Sarah Soorya2, Richard Miller4, Rachel Miller1 and Anne-Marie Malfait2, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, Chicago, 3Rush University, Chicago, 4Northwestern University, Chicago

    Background/Purpose: Nociceptors abundantly innervate the knee joint. In experimental osteoarthritis (OA), nociceptors sprout in the medial synovium and in subchondral bone channels. We aimed to…
  • Abstract Number: 1768 • ACR Convergence 2025

    TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis

    Lea Dionet1, Alexandre Lanau2, Paul Breillat3, Quentin Delcros4, Federica Pallotti5, Margot Poux6, Pierre Isnard1, Arthur Lavigne4, Xavier Puéchal7, alexandre karras8, Jean-Paul Duong9, Olivia Lenoir10, Pierre-Louis Tharaux11 and Benjamin Terrier12, 1INSERM, Paris, France, 2Institut Curie, Paris, France, 3INSERM, PARIS 17, Ile-de-France, France, 4AP-HP, Paris, France, 5Internal Medicine and Clinical Immunology, Rennes, France, 6Université de Paris, PARIS 04EME, France, 7Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 8HEGP - assistance publique hopitaux de paris, paris, France, 9INSERM, Paris, 10Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, Ile-de-France, France, 11Paris Cardiovascular Research Center, Université Paris Cité, INSERM U970, Paris, France, PARIS, France, 12Cochin Hospital, Paris, France

    Background/Purpose: ANCA-associated vasculitis (AAV) is a small-vessel vasculitis that can lead to life-threatening renal injury. Neutrophils, monocytes and macrophages play a pivotal role not only…
  • Abstract Number: L02 • ACR Convergence 2024

    Persistent Articular Infection and Host Reactive Responses Contribute to Brucella-Induced Spondyloarthritis in SKG Mice

    Jerome Harms1, Jens Eickhoff1, Thomas Warner1 and Judith Smith2, 1University of Wisconsin-Madison, Madison, WI, 2University of Wisconsin, Madison, WI

    Background/Purpose: Brucellosis, one of the most prevalent zoonotic diseases worldwide, often results in osteoarticular complications including large joint and axial arthritis mimicking spondyloarthritis (SpA). Greater…
  • Abstract Number: 0929 • ACR Convergence 2024

    UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin

    Ahmed Eldaboush1, Cristina Ricco1, Luca Musante1, Rohan Dhiman2, Avital Baniel3, Daniella Faden1, Caroline Stone1, Ming-Lin Liu1 and Victoria Werth4, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Newport Coast, CA, 3Perelman School of Medicine, UPENN, Philadelphia, PA, 4University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Extracellular vesicles (EVs) are small lipid-bilayer particles released from cells that mediate various functions through their cargo, which includes proteins and nucleic acids. EVs…
  • Abstract Number: 0959 • ACR Convergence 2024

    Radiomics Non-Invasively Conveys Time-Resolved Molecular Pathway Activity in Experimental Fibrosing Interstitial Lung Disease

    David Lauer1, Matthias Brunner2, Hubert Gabrys3, Kerstin Klein2, Oliver Distler4, Britta Maurer5 and Janine Gote-Schniering2, 1University Hospital Bern, Bern, Switzerland, 2University of Bern, Bern, Switzerland, 3University Hospital Zurich, Zurich, Zurich, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 5University Hospital Bern, University Bern, Bern, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in patients with autoimmune-related CTD such as SSc and RA. Molecular characterization of the…
  • Abstract Number: 1154 • ACR Convergence 2024

    Comparative Transcriptome Analysis of Murine Model and Human Samples in Anti-Melanoma Differentiation Associated Gene 5 Antibody-positive Rapidly Progressive Interstitial Lung Disease

    Yuki Ichimura1, Risa Konishi2, Tadatsune Iida3, Kousuke Negishi4 and Naoko Okiyama5, 1Tokyo Women’s Medical University, Tokyo, Japan, 2University of Tsukuba, Tokyo, Japan, 3Institute of Science Tokyo, Tokyo, Japan, 4Kawakita General Hospital, Tokyo, Japan, 5Institute of Science Tokyo, Toky, Japan

    Background/Purpose: Anti-Melanoma differentiation associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) frequently presents with rapidly progressive interstitial lung disease (RP-ILD), leading to a high mortality rate…
  • Abstract Number: 1656 • ACR Convergence 2024

    Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis

    Katherine Escalera-Rivera, Jennifer Jonason and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Osteoarthritis (OA) is a complex disease involving pathological processes in joint tissues such as the cartilage and synovium. Cartilage is degraded by matrix metalloproteinases…
  • Abstract Number: 1776 • ACR Convergence 2024

    Animal Models of Pediatric MOGAD

    Yike Jiang1, Elliot Lin2, Estefany Reyes2, Devon DiPalma2, Sundar Khadka2, Heather Van Mater2 and Mari Shinohara2, 1Duke Univerisity, Durham, NC, 2Duke University, Durham, NC

    Background/Purpose: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a devastating demyelinating disease that disproportionally affects children. Discovered in 2018, MOGAD is now internationally recognized as…
  • Abstract Number: 1815 • ACR Convergence 2024

    Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel

    Lauren Reinke-Breen1, Laura Leys1, Sunhwa Kim2, Lauren Olson1, Anastasia Marinopoulos1, Chris Butler1, Jennifer Van Camp1 and Lisa Hazelwood1, 1AbbVie, North Chicago, IL, 2AbbVie, South San Francisco, CA

    Background/Purpose: Systemic sclerosis (SSc) is a chronic, progressive autoimmune disorder with significant morbidity and mortality. The lack of effective therapies for SSc is, in part,…
  • Abstract Number: 1841 • ACR Convergence 2024

    Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases

    Kristen Zhang, Joanne Li, Duy Nguyen, Nguyen Tan, Hsin-Yuan Cheng, David Huang, Suhasni Gopalakrishnan, Zachary Roberts, Cesar Sommer and Elvin Lauron, Allogene Therapeutics, South San Francisco, CA

    Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…
  • Abstract Number: 2462 • ACR Convergence 2024

    A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis

    Enming Su1, Pei-Suen Tsou1, Mark Warnock2, Natalya Subbotina1, Kris Mann1, Sirapa Vichaikul1, Xianying Xing1, Enze Xing1, Olesya Plazyo1, Rachael Wasikowski1, Lam C. Tsoi3, Mark Weinberg4, Cory D. Emal5, Dinesh Khanna1, John Varga1, Thomas H. Sisson1, Johann Gudjonsson1 and Daniel Lawrence2, 1University of Michigan, Ann Arbor, MI, 2Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 3Michigan, Dept. of Dermatology, Ann Arbor, MI, 4MDI, Ann Arbor, MI, 5EMU, Ann Arbor, MI

    Background/Purpose: Systemic sclerosis (SSc) is a complex and heterogeneous condition characterized by progressive fibrosis in multiple organs. Currently, there is no known cure for SSc,…
  • Abstract Number: 0014 • ACR Convergence 2024

    Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease

    Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego

    Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
  • Abstract Number: 0019 • ACR Convergence 2024

    A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles

    Theresa Hunter1, Ferran Soldevila1, Yan Zhang1, Brittany Ross1, Daiki Matsuda1, Yanjie Bao1, John Li1, Michelle Nguyen1, Matthew Butcher1, MIchael Pica1, Claudia Fernandez1, James Vestal1, Goutam Mondal1, Yi Kuo1, Jeffrey Chen1, Josephine Nguyen2, Young Yoon Choi2, Diana Galvan1, Duy Nguyen1, Donald Jhung2, Stuart Sievers1, Steven Tanis1, Cory Bentley2, Michael Rosenzweig1, Priya Karmali1, Adrian Bot1, Haig Aghajanian1 and Gregor Adams1, 1Capstan Therapeutics, San Diego, CA, 2Capstan Therapeutics, San Diego

    Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
  • Abstract Number: 0025 • ACR Convergence 2024

    Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis

    Shivmurat Yadav1, Timothy Griffin2, Matlock Jeffries2, Stavros Stavrakis3 and Mary Beth Humphrey4, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3University of Oklahoma, College of Mediicine, Oklahoma City, OK, 4University of Oklahoma College of Medicine, Oklahoma City, OK

    Background/Purpose: Osteoarthritis (OA) causes joint pain, stiffness, swelling, and functional impairment. Pain signals reach the brain, influencing inflammatory and immune responses through the parasympathetic efferent…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology